• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Opinions
    • Top 30
    • Research
    • Supply Chain
    • Device Sectors
    • Directory
    • Events
    • Resources
    • Microsites
    • More
  • Magazine
  • News
  • Opinions
  • Top 30
  • Research
  • Supply Chain
  • Device Sectors
  • Directory
  • Events
  • Resources
  • Microsites
  • Current / Back Issues
    Features
    Editorial
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Reprints
    Subscribe Now
    Advertise Now
    Top Features
    Adding Fabrication Capabilities: Additive Manufacturing for Production Parts

    Delivering the Goods: The Evolving World of Combination Products

    Anxious Undertones: The 2019 Year in Review

    From Art to Science: The Changing Face of Extrusion

    Exact Science: A Micromolding Roundtable
    OEM News
    Supplier News
    Service / Press Releases
    Online Exclusives
    Press Releases
    People in the News
    Product & Service Releases
    Supplier News
    Technical Features
    International News
    Videos
    Product & Service Releases
    Live From Shows
    Top News
    FDA OKs Roche's Nasal Swab MRSA Test

    Philips & Paige to Deliver Clinical-Grade AI Applications to Pathology Labs

    Eye Test for Parkinson's Gains Breakthrough Designation

    Biomerics Forms New Business Unit

    J&J's New Monofocal IOL for Cataract Patients with Astigmatism
    From the Editor
    Blogs
    Guest Opinions
    Top Opinions
    Adding Fabrication Capabilities: Additive Manufacturing for Production Parts

    Delivering the Goods: The Evolving World of Combination Products

    Anxious Undertones: The 2019 Year in Review

    From Art to Science: The Changing Face of Extrusion

    Exact Science: A Micromolding Roundtable
    Top 30 Medical Device Companies
    Market Data
    White Papers
    Top Research
    From Genome Sequencing to the World’s First Portable MRI

    An Update on Digital Health

    ‘If You’re Reading This, You Need to Be at This Meeting’

    Five Steps for Succeeding Globally in Medtech

    Unlocking Market Doors with Real-World Evidence
    3D/Additive Manufacturing
    Contract Manufacturing
    Electronics
    Machining & Laser Processing
    Materials
    Molding
    Packaging & Sterilization
    R&D & Design
    Software & IT
    Testing
    Tubing & Extrusion
    Cardiovascular
    Diagnostics
    Digital Health
    Neurological
    Patient Monitoring
    Surgical
    All Companies
    Categories
    Company Capabilities
    Add New Company
    Outsourcing Directory
    K-Tube Technologies

    Halkey-Roberts Corporation

    Accumold

    S-Y-M Products Company

    NN Life Sciences/Paragon Medical
    MPO Summit
    Industry Events
    Webinars
    Live From Show Event
    Industry Associations
    Videos
    Career Central
    eBook
    Slideshows
    Top Resources
    Understanding Key Processes for Mixing APIs with Silicone

    How to Minimize Color Variations in Your Medical Device

    Don’t Touch: Gesture Tech Is Reshaping How We Interact with Devices

    Revenue-Based Financing: A New Form of Growth Capital

    Pre-Filled Safety Syringes and the Self-Administration Trend
    Companies
    News Releases
    Product Releases
    Press Releases
    Product Spec Sheets
    Service Releases
    Case Studies
    White Papers
    Brochures
    Videos
    Outsourcing Directory
    Carclo Technical Plastics

    IQMS

    NN Life Sciences/Paragon Medical

    GS Plastic Optics

    Command Medical Products Inc.
    • Magazine
      • Current/Back Issues
      • Features
      • Editorial
      • Columns
      • Digital Editions
      • Subscribe Now
      • Advertise Now
    • News
    • Directory
      • All Companies
      • ALL CATEGORIES
      • Industry Associations
      • Company Capabilities
      • Add Your Company
    • Supply Chain
      • 3D/Additive Manufacturing
      • Contract Manufacturing
      • Electronics
      • Machining & Laser Processing
      • Materials
      • Molding
      • Packaging & Sterilization
      • R&D & Design
      • Software & IT
      • Testing
      • Tubing & Extrusion
    • Device Sectors
      • Cardiovascular
      • Diagnostics
      • Digital Health
      • Neurological
      • Patient Monitoring
      • Surgical
    • Top 30 Company Report
    • Expert Insights
    • Slideshows
    • Videos
    • Podcasts
    • Resources
    • eBook
    • Infographics
    • Whitepapers
    • Research
      • White Papers
      • Case Studies
      • Product Spec Sheets
      • Market Data
    • MPO Summit
    • Events
      • Industry Events
      • Live From Show Events
      • Webinars
    • Microsite
      • Companies
      • Product Releases
      • Product Spec Sheets
      • Services
      • White Papers / Tech Papers
      • Press Releases
      • Videos
      • Literature / Brochures
      • Case Studies
    • About Us
      • About Us
      • Contact Us
      • Advertise with Us
      • eNewsletter Archive
      • Privacy Policy
      • Terms of Use
    Columns

    Trends, Opportunities, and Drivers in Early-Stage Life Sciences Investing

    Despite trade wars and economic shifts in China and the EU, early-stage investing in life sciences remained strong in Q1 2019.

    Trends, Opportunities, and Drivers in Early-Stage Life Sciences Investing
    Related CONTENT
    • FDA to Closely Examine Surgical Stapler Risks
    • FDA Warns J&J and Sientra for Breast Implant Compliance Failure
    • FDA to Modernize Mammography Services and Improve Their Quality
    • A New, Tailored Review Framework for Artificial Intelligence-Based Devices
    • FDA OKs Coag-Sense Second-Generation PT/INR Monitoring System
    Byron S. Kalogerou, Partner, McDermott Will & Emery09.06.19
    It’s a great time to be an early-stage life sciences company. Significant funding continues to roll into this sector, driven by legacy venture capital (VC) funds bringing in new dollars, new players that are out-raising their targets, and active corporate venture capital players. Despite trade wars and economic shifts in China and the EU, early-stage investing in life sciences, particularly in the biotechnology and medical devices sectors, remained strong in Q1 2019, improving quarter over quarter with more than $2.8 billion invested into the space. The confluence of funding and an innovation-friendly regulatory environment provide early-stage life sciences companies with ample opportunity to bring their solutions to market. This article explores the factors driving opportunity in this investment space, as well as how investors and companies can position themselves as attractive partners.

    Getting Innovation to Market and Subsectors to Watch
    Recent actions by the U.S. Congress and leadership at the U.S. Food and Drug Administration (FDA) have demonstrated regulatory support for innovative life sciences solutions. Numerous programs, such as the FDA’s Breakthrough Designation Program for medical devices and the Digital Health Precertification Program, among others, have allowed companies to work more closely with regulators, communicate with them prior to approval submissions, and bring products to market more rapidly, while still maintaining patient safety. These programs, which require fewer data submissions at the outset in exchange for increased post-market study and surveillance obligations, can allow companies with smaller budgets to get their product to market earlier.

    Coinciding with the shift in focus from treatment to cure, from status quo to innovation, the first generation of gene cell therapies have arrived, along with a new wave of digital health applications that employ artificial intelligence (AI) and machine learning (ML). New tools, diagnostics, and devices are reshaping the way patients receive treatment across the spectrum of care. These exciting breakthroughs are accelerating discovery and creating a better understanding of the mechanism of action—which, in turn, gives better insight into clinical outcomes, giving investors a more predictable return. Particularly ripe subsectors for investment as indicated by Q1 2019 performance and regulatory attention include:
    • AI and ML: From diagnosing tumors to matching patients to clinical trials, the staggering amount of data collected in the life sciences space presents numerous use cases for AI and ML solutions. While implementation challenges remain, a recent FDA white paper on its efforts to develop a framework for regulating AI products, along with two AI-based devices approved by the agency in 2018, are promising for investors and developers alike. Investors and analysts have taken note, with AI in the life sciences space valued at $902.1 million (forecasted 2019-2024).
    • Medical Devices: Funding for medical devices saw a 7 percent quarter over quarter increase to $701 million in Q1 2019. The FDA’s Breakthrough Device Program, which has granted 112 Breakthrough Designation Requests as of January 2019, is one example of the supportive regulatory environment and a contributing factor to the funding increases seen in this life sciences subsector.
    Transformation-Driven Partnerships: Evaluating and Attracting Targets
    Within this dynamic landscape, early-stage life sciences companies and investors are forming mutually profitable partnerships to bring transformative products to market faster and more efficiently. Life sciences companies can take strategic steps to enhance their value as a potential investment target. When evaluating targets, investors often look for the following elements:
    • Innovation and unmet need. Novel products, therapies, or approaches that address an unmet need in the market are good candidates for investment.
    • The right team. It is often easier to find good technology than good managers, according to some investors. A life sciences company with a well-run team and strong leadership in place makes for a more attractive investment partner. Effective leaders who can clearly articulate the path to commercialization and the cost to do so will attract investment dollars.
    • Cross-border application. More than ever, investors are looking for products that can enter multiple markets, including Europe and Asia Pacific, because an expanded geographic approach can increase returns. Devices and other products that have application to China’s burgeoning market are a particularly hot focus for investors.
    • Opportunities to add value. Many investors seek out targets that present compelling and quantifiable propositions to drive significant costs out of the healthcare system while improving health outcomes. Investors are not seeking opportunities for marginal savings, but rather transformative “move the needle” innovation.
    To set the stage for an effective investment partnership, life sciences companies should reach out early and often to potential investors, well before they are actually looking to raise capital. Attending industry and well-orchestrated partnering events like Life Science Nation’s RESI series can be a good opportunity to connect and develop relationships with a host of potential investors. Investors don’t just invest in a product—they invest in a team—so face-to-face interaction can lay valuable groundwork for a potential partnership. Curating those contacts through counsel, an accountant, and/or banker can reap dividends over time.

    In addition to evaluating whether a partnership is a good fit from a leadership and culture perspective, investors will often consider the following questions when evaluating a potential target—being prepared to speak directly and clearly to these points, as well as to specific goals for the partnership, will allow for a much more fruitful conversation with a potential investor.
    • What is the regulatory risk? What will it take to get the company through the next regulatory milestones in all relevant jurisdictions? Is it reasonable to expect the device or product to be approved globally at the same time, or will there be regulatory lag? What level of investment will it take to get the product into a clinic and generate the necessary clinical data? Investors today are increasingly conditioning funding on these regulatory milestones.
    • What is the reimbursement pathway? With regulatory approval achieved, revenue can only be achieved by executing a reimbursement strategy that addresses coverage, coding, and payment. After satisfying investors on the ability to secure coverage determination and coding, investors will focus on the pricing of a product to assess the sales potential.
    • Does the company have a clear inflection point it is trying to reach? If a life sciences company can’t articulate a specific, discrete strategy for how it will use the funding to develop or commercialize the product, investors may pass on the opportunity.
    • What is the competitive landscape? How big is the market opportunity in various jurisdictions? This evaluation should take into account not just the general consumer or patient pool, but also specific practicalities, such as the number of patients willing to pay a given price for the product, or the treatment paradigms that come into play. Having a good grasp of these specifics can improve conversations with potential investors, because it reduces the amount of uncertainty they will have to devote time and resources to address.
    • What is the exit opportunity? We often counsel our early-stage clients to “begin with the end in mind.” Life sciences investors will want to hear a clearly articulated vision of the exit. Will the company be seeking to access the capital markets in an initial public offering, looking for an exit through an acquisition, or seek to out-license the technology? In the case of an M&A exit or an out-license, companies should identify each of the potential suitors with whom they envision they will one day conduct a deal.

    Changing economic and political environments aside, the life sciences market presents exciting opportunities for early-stage life sciences companies and the investors who believe and invest in them. Early-stage firms with defined strategic goals, an innovative product addressing unmet need and a compelling value proposition, effective leadership, and above all, an exit strategy that enables investors to achieve the returns they are seeking, can position themselves to attract the right investors to bring their solutions to market. 


    Byron S. Kalogerou is the founder of the McDermott Will & Emery’s Life Science Industry Group and the senior attorney in the Boston Corporate Practice. He focuses his practice on domestic and cross-border mergers and acquisitions, finance, and joint ventures and alliances. He has substantial on-the-ground experience structuring mergers, acquisitions, divestitures, and joint ventures on six continents. Byron has extensive industry background in the life sciences, industrial, and manufacturing sectors. He also acts as outside general counsel to a number of companies.
    Related Searches
    • needle
    • data
    • digital health
    • paper
    Suggested For You
    Globalization: Will Your 2019 Regulatory Strategy Help You Win in 2020? Globalization: Will Your 2019 Regulatory Strategy Help You Win in 2020?
    First Come, First Served:  Class I Manufacturers Stand in Line for EU MDR Certification First Come, First Served: Class I Manufacturers Stand in Line for EU MDR Certification
    The Legacy of Apple Health The Legacy of Apple Health
    The Benefits of Software-Powered Electronics Manufacturing The Benefits of Software-Powered Electronics Manufacturing
    FDA Advises Transition to Disposable Duodenoscopes FDA Advises Transition to Disposable Duodenoscopes
    Inochi Care Wins at Medtech Innovator Pitch Event Inochi Care Wins at Medtech Innovator Pitch Event
    Messe Düsseldorf to Organize Medical Fair Brasil Messe Düsseldorf to Organize Medical Fair Brasil
    7th Annual Pediatric Device Innovation Symposium in Boston 7th Annual Pediatric Device Innovation Symposium in Boston
    New CEO at NeuroPace New CEO at NeuroPace
    Automation: The First Step to Industry 4.0 Automation: The First Step to Industry 4.0
    FDA Shares Progress on Efforts to Increase Transparency in Medical Device Reporting FDA Shares Progress on Efforts to Increase Transparency in Medical Device Reporting
    MedTech Innovator Selects 50 Best-in-Class Startups for 2019 Showcase and Accelerator MedTech Innovator Selects 50 Best-in-Class Startups for 2019 Showcase and Accelerator
    Connected Quality Systems Reduce Risks Connected Quality Systems Reduce Risks
    Developing Market Access Strategies Developing Market Access Strategies
    FDA Approves Device to Help Increase Access to More Lungs for Transplant FDA Approves Device to Help Increase Access to More Lungs for Transplant

    Related Columns

    • Diagnostics
      From Genome Sequencing to the World’s First Portable MRI

      From Genome Sequencing to the World’s First Portable MRI

      Dr. Jonathan Rothberg has risen about as high as a scientist can, save for the Nobel Prize.
      Sam Brusco, Associate Editor 11.04.19

    • Digital Health
      An Update on Digital Health

      An Update on Digital Health

      Sure, most are startups—but not all. There were some brilliant ideas presented at The MedTech Conference (AdvaMed’s annual meeting) on Sept. 23-25 in Boston and the Connected Health Conference, also in Boston, put on by Partners Health…
      Maria Shepherd, President and Founder, Medi-Vantage 11.04.19

    • ‘If You’re Reading This, You Need to Be at This Meeting’

      ‘If You’re Reading This, You Need to Be at This Meeting’

      The AAOS/FDA/Industry Townhall is taking place March 24, 2020, at the AAOS annual meeting in Orlando.
      Dawn A. Lissy, President & Founder, Empirical 11.04.19


    • Five Steps for Succeeding Globally in Medtech

      Five Steps for Succeeding Globally in Medtech

      World views can differ considerably, so it is important to understand, appreciate, and respect cultural realities and differences.
      Florence Joffroy-Black and Dave Sheppard, MedWorld Advisors 11.04.19

    • Software & IT
      Unlocking Market Doors with Real-World Evidence

      Unlocking Market Doors with Real-World Evidence

      Real-world evidence is becoming increasingly important for manufacturers to demonstrate value beyond efficacy and safety standards.
      Seth Goldenberg, Ph.D., Vice President, Vault Medical Device & Diagnostics, Veeva Systems 11.04.19

    • Contract Manufacturing
      Sales Tips for Contract Manufacturers of Finished Devices

      Sales Tips for Contract Manufacturers of Finished Devices

      Evolving trends in the supply chain may require companies to consider a strategy of selling devices of their own design.
      Tony Freeman, President, A.S. Freeman Advisors LLC 11.04.19


    • Impeachment, Executive Orders, and Must-Pass Congressional Legislation: A Fall Update

      Impeachment, Executive Orders, and Must-Pass Congressional Legislation: A Fall Update

      The final quarter of 2019 has begun, which means Congress and the Trump Administration are hard at work finalizing healthcare initiatives before year's end.
      Jeffrey J. Kimbell, David C. Rudloff and Caroline P. Tucker, Jeffrey J. Kimbell & Associates Inc. 11.04.19

    • R&D & Design
      Perfecting Drug Delivery Device Design

      Perfecting Drug Delivery Device Design

      Unlike medical products that just need to work, drug delivery devices must also consider intuitiveness, usability, and how it makes the user feel when operated.
      Bryce G. Rutter, Ph.D., Founder & CEO, Metaphase Design Group Inc. 11.04.19

    • Diagnostics
      Elizabeth Holmes: The Making of a Pop Culture Icon

      Elizabeth Holmes: The Making of a Pop Culture Icon

      Despite keeping a relatively low profile this year (not by choice), Elizabeth Holmes’ celebrity status has continued to grow.
      Michael Barbella, Managing Editor 10.08.19


    • A Look at Physician/Surgeon Salary and Employment Statistics

      A Look at Physician/Surgeon Salary and Employment Statistics

      No more call for physicians? Not really, but schedule predictability is in for physicians.
      Maria Shepherd, President and Founder, Medi-Vantage 10.08.19

    • Bridging Generation Gaps to Build Better Teams and Business

      Bridging Generation Gaps to Build Better Teams and Business

      I’ve learned the hard way that building teams of motivated, productive employees is equal parts science and art.
      Dawn A. Lissy, President & Founder, Empirical 10.08.19

    • Testing
      Managing Risks for Medical Devices:  A Guide to Understanding ISO 14971

      Managing Risks for Medical Devices: A Guide to Understanding ISO 14971

      The intent of ISO 14971 is to provide a general “bird’s-eye view” approach to designing and implementing a risk management plan for medical devices.
      Helin Räägel, Ph.D., Biocompatibility Expert, Nelson Labs 10.08.19

    • Testing
      Preparing for MDR: Test In-House or Outsource?

      Preparing for MDR: Test In-House or Outsource?

      As the EU MDR deadline draws near, manufacturers are under pressure to bring products into compliance and get submissions in front of regulators ASAP.
      Sandi Schaible, Senior Director, Analytical Chemistry and Regulatory Toxicology, WuXi Medical Device Testing 10.08.19

    • Think Chinese Tariffs Are the Only Industry Job Killers? Think Again

      Think Chinese Tariffs Are the Only Industry Job Killers? Think Again

      One of the latest concerns—arising from an old issue—is the medical device tax, which could return next year without legislative intervention before then.
      Florence Joffroy-Black and Dave Sheppard, MedWorld Advisors 10.08.19

    • Contract Manufacturing | Software & IT
      Five Ways Quality 4.0 Is Changing the Face of Medical Device Manufacturing

      Five Ways Quality 4.0 Is Changing the Face of Medical Device Manufacturing

      Industry 4.0 represents the dawn of the digital transformation that began with the third revolution, connecting the physical and natural worlds.
      Scott Reedy, Senior Director of Marketing, Arena Solutions 10.08.19


    Breaking News
    • FDA OKs Roche's Nasal Swab MRSA Test
    • Philips & Paige to Deliver Clinical-Grade AI Applications to Pathology Labs
    • Eye Test for Parkinson's Gains Breakthrough Designation
    • Biomerics Forms New Business Unit
    • J&J's New Monofocal IOL for Cataract Patients with Astigmatism
    View Breaking News >
    CURRENT ISSUE

    November/December 2019

    • Adding Fabrication Capabilities: Additive Manufacturing for Production Parts
    • Delivering the Goods: The Evolving World of Combination Products
    • Anxious Undertones: The 2019 Year in Review
    • View More >
    • About Us
    • Privacy Policy
    • Terms And Conditions
    • Contact Us

    follow us

    Subscribe
    Nutraceuticals World

    Latest Breaking News From Nutraceuticals World

    International Scientific Society Calls for Omega-3 Blood Testing in Future Research
    Pharmactive Affron Saffron May Help Relieve Depression Symptoms
    Warmer Temperatures Could Lead to Concerning Levels of Arsenic in Rice
    Coatings World

    Latest Breaking News From Coatings World

    Cristo Rey High School Educator Named 2019 Axalta All-Pro Teacher of the Year
    Michelman Makes United Way of Greater Cincinnati’s List of Top 25 Corporate Campaigns
    BCF: Coatings Industry Reports Record Improvement in Waste, Recycling, Accident Rates
    Medical Product Outsourcing

    Latest Breaking News From Medical Product Outsourcing

    FDA OKs Roche's Nasal Swab MRSA Test
    Philips & Paige to Deliver Clinical-Grade AI Applications to Pathology Labs
    Eye Test for Parkinson's Gains Breakthrough Designation
    Contract Pharma

    Latest Breaking News From Contract Pharma

    Almac Awarded $1M BMGF Grant
    Vivera Pharma, Parexel Ink Clinical Services Agreement
    MedPharm Triples Capacity at RTP Site
    Beauty Packaging

    Latest Breaking News From Beauty Packaging

    WWP Wins Three NJPEC Awards
    Cat-Themed Beauty Collection to Launch in Japan
    Pantone Names Classic Blue the 2020 Color of the Year
    Happi

    Latest Breaking News From Happi

    Lip Lab Opening in Brooklyn
    Raining Rose Expands Exec Team
    Scott’s Sells Personal Care Production Site
    Ink World

    Latest Breaking News From Ink World

    ePac Flexible Packaging Expands into Asia Pacific Market
    Haney, HP Developing Sustainable Fashion Packaging for Heron Preston
    Addipel Moves to New HQ, Expands Production Facility
    Label & Narrow Web

    Latest Breaking News From Label & Narrow Web

    HP teams with Haney for sustainable packaging
    Tags & Labels Printing adds Heidelberg’s Versafire EP
    Austrian converter installs first Nilpeter press
    Nonwovens Industry

    Latest Breaking News From Nonwovens Industry

    Thrace to Relocate U.S. Capacity
    FiltXPO Speaker Line-Up Announced
    Nölken Incorporates Sustainable Wipes Packaging
    Orthopedic Design & Technology

    Latest Breaking News From Orthopedic Design & Technology

    Orthofix Appoints New Spine Business Leader
    Viant to Halt EtO Sterilization at Michigan Plant by End of Year
    Synaptive Medical's Modus V Expands Into Spine Market
    Printed Electronics Now

    Latest Breaking News From Printed Electronics Now

    IDTechEx Show! Announces Graphene Award Winner
    OE-A Continues to Bring Future of Printed Electronics to CES 2020
    Avancis, Smit Thermal, HZB, CNRS, Solliace Team for Higher Efficiencies in CIGS

    Copyright © 2019 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.